Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan

Share this postShare on Google+Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

Medications that reduce inflammation known as non-steroidal anti-inflammatory drugs (NSAIDS) do not improve thinking abilities in normal seniors.  These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that took part in this study that was supported by the Federal Government. The Tampa clinic enrolled over 400 seniors (age 70 or older) with at least one relative with a dementia. The group was studied for 5 years, undergoing memory testing every year. Two-thirds of the participants received NSAIDS, either Naproxen, or Celecoxib, and one- third, a sugar pill. The study reports that one of the treatments (Naproxen) may contribute to worsening memory or other mental abilities. However further study is needed to determine if these finding persists over time, or if seniors who performed worse on memory testing were experiencing the early signs of a dementia.Drs. Cheryl Luis and Timothy Crowell, specialists in Neuropsychology, supervised the day-to-day aspects of the study in Tampa. Dr. Michael Mullan, director of the Roskamp Institute and principal investigator. Also please read other interesting articles at the Dr. Mullan’s Alzheimer Research notes website: http://www.mullanalzheimer.com